Proqr Therapeutics Eo 04 Stock Beneish M Score
| 0PQ Stock | EUR 3.40 0.01 0.29% |
PROQR |
At this time, PROQR THERAPEUTICS's M Score is inapplicable. The earnings manipulation may begin if PROQR THERAPEUTICS's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by PROQR THERAPEUTICS executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of PROQR THERAPEUTICS's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-4.84
Beneish M Score - Inapplicable
Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
About PROQR THERAPEUTICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PROQR THERAPEUTICS EO 04's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PROQR THERAPEUTICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PROQR THERAPEUTICS EO 04 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in PROQR Stock
PROQR THERAPEUTICS financial ratios help investors to determine whether PROQR Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PROQR with respect to the benefits of owning PROQR THERAPEUTICS security.